Mary Szela

Mary Szela

CEO and PresidentatTriSalus Life Sciences· In proxies 2022–2025

Pay in FY2025+17% from the year before · TriSalus Life Sciences stock +39.3% the same year

Mary Szela was paid $4.8M in FY2025 (Dec), up 17%. TriSalus Life Sciences stock rose 39.3% that year.

Pay$100 in the stock at the end of FY21 → $71
Pay is from the Summary Compensation Table of each TriSalus Life Sciences proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. TriSalus Life SciencesPublic company · 4 yr
    • CEO and President2022 – Present · 4 yrStock in role -60%
  2. Clene NanomedicinePublic company
    • Director? – PresentNo stock prices for these years
  3. Directors for FlindrPublic company
    • Director? – PresentNo stock prices for these years
  4. Empyrean NeurosciencePublic company
    • Director? – PresentNo stock prices for these years
  5. Obvius Robotics, Inc.Public company
    • Director? – PresentNo stock prices for these years
  6. Openwater Software, Inc.Public company
    • Director? – PresentNo stock prices for these years
  7. Pathology WatchPublic company
    • Director? – PresentNo stock prices for these years
  8. PhotonPharma Inc.Public company
    • Director? – PresentNo stock prices for these years
  9. Tympa Health Technologies LtdPublic company
    • Director? – PresentNo stock prices for these years
  10. UP OncolyticsPublic company
    • Director? – PresentNo stock prices for these years
  11. WespePublic company
    • Director? – PresentNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?